Loading...
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
Mantle cell lymphoma (MCL) is a type of non-Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on resu...
Na minha lista:
| Udgivet i: | Am J Hematol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6896320/ https://ncbi.nlm.nih.gov/pubmed/28699256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24854 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|